Extent of platelet aggregation inhibition and clinical events: New evidence with prasugrel;Entità dell'inibizione dell'aggregazione piastrinica ed eventi clinici: Nuove evidenze ottenute con prasugrel

Giornale Italiano di Cardiologia

Volumn 11, Issue 2, 2010, Pages 127-137

  Abbate, Rosanna ^a   Crea, Filippo ^b   De Servi, Stefano ^c   Filippi, Erica ^d   Gensini, Gian Franco ^a   Golino, Paolo ^e   Savonitto, Stefano ^f  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Ospedale Civile   (Italy)

^d Eli Lilly Italia   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f Dipartimento Cardiologico A De Gasperis   (Italy)

Author keywords

Antiplatelet therapy; Clopidogrel; Platelets; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; BLEEDING; BODY WEIGHT; HEART MUSCLE ISCHEMIA; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; RESPONSE VARIABLE; REVIEW; THROMBOCYTE; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77949411562     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Morant SV, McMahon AD, Cleland JG, Davey PG, MacDonald TM. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 2004; 57: 188-98.
3. Sullivan J, Amarshi N. Dual antiplatelet therapy with clopidogrel and aspirin. Am J Health Syst Pharm 2008; 65: 1134-43.
4. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
6. Steinhubl SR, Berger PB, Mann JT 3rd, et al, for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
7. Main C, Palmer S, Griffin S, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004; 8: 1-141.
8. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2000; (2): CD001246.
9. Chen ZM, Jiang LX, Chen YP, et al, for the COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.
10. Sabatine MS, Cannon CP, Gibson CM, et al, for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
11. Mehta SR, Yusuf S, Peters RJ, et al, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.
13. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007; 115: 2196-207.
14. Gladding P, Webster M, Ormiston J, Olsen S, White H. Antiplatelet drug nonresponsiveness. Am Heart J 2008; 155: 591-9.
15. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to review new evidence and update the ACC/AHA/SCAl 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 Writing Committee. Circulation 2008; 117: 261-95.
16. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15-22.
17. Serebruany VL. Plasma clopidogrel metabolites and antiplatelet "resistance": back to the future. Thromb Res 2008; 122: 725-6.
18. Lau WC, Gurbel PA, Warkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-71.
19. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72: 313-7.
20. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-7.
21. Gurbel PA, Cummings CC, Bell CR, et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003; 145: 239-47.
22. Wienbergen H, Gitt AK, Schiele R, et al, for the MITRA PLUS Study Group. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92: 285-8.
23. Saw J, Steinhubl SR, Berger PB, et al, on behalf of the clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-4.
24. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004; 164: 2051-7.
25. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735-41.
26. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-bind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-60.
27. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-8.
28. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
29. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-9.
30. Stanek EJ, Aubert RE, Flockhart DA, et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting. The Clopidogrel in Medco Outcomes Study. http://www.scai.org/pdf/20090506Medcoabstract.pdf [accessed September 18, 2009].
31. FDA US Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders [accessed September 18, 2009].
32. European Medicines Agency (EMEA). Public statement on possible interaction between clopidogrel and proton pump inhibitors. http://www.emea. europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf [accessed September 18, 2009].
33. Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-6.
34. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 2005; 112: 2946-50.
35. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A4-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-94.
36. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-7.
37. Brandt JT, Kirkwood S, Mukhopadhyay N, et al. CYP2C19*2 polymorphism contributes to a diminished pharmacodynamic response to clopidogrel [abstract]. J Am Coll Cardiol 2006; 47: 380A.
38. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007; 17: 1057-64.
39. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009; 103: 806-11.
40. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
41. Simon T, Verstuyft C, Mary-Krause M, et al, for the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.
42. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-17.
43. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-22.
44. Marcucci R, Gori AM, Paniccia R, et al. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis 2007; 195: e217-e223.
45. Cesari F, Marcucci R, Caporale R, et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99: 930-5.
46. Ang L, Palakodeti V, Khalid A, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008; 52: 1052-9.
47. Chung I, Lip GY. Platelets and heart failure. Eur Heart J 2006; 27: 2623-31.
48. Gori AM, Cesari F, Marcucci R, et al. The balance between pro-and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009; 202: 255-62.
49. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-31. La prima metanalisi che ha dimostrato un aumento del rischio di eventi clinici avversi in pazienti con reattività piastrinica residua in corso di terapia con clopidogrel.
50. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-50.
51. Marcucci R, Paniccia R, Antonucci E, et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 2007; 98: 844-51.
52. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-7. Il RECLOSE trial ha dimostrato un significativo aumento del rischio di trombosi su stent medicato in 683 pazienti ad un follow-up di 6 mesi.
53. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-43.
54. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
55. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention: results of the ARMYDA-PRO (Antiplatelet therapy for reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008; 52: 1128-33. In un sottogruppo di 160 pazienti la reattività piastrinica residua misurata con test point-of-care predice l'insorgenza di eventi cardiaci maggiori avversi a 30 giorni.
56. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-42.
57. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-9.
58. Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-47.
59. Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J 2008; 156 (2 Suppl): S16-S22.
60. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66.e9-e16.
61. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-73.
62. Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99: 215-22.
63. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-74.
64. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
65. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009; 30: 1744-52.
66. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-60.
67. Wiviott SD, Antman EM, Winters KJ, et al, for the JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366-73. Studio di fase II di sicurezza su prasugrel.
68. Wiviott SD, Trenk D, Frelinger AL, et al, for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-32.
69. Wiviott SD, Antman EM, Gibson CM, et al, for the TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006; 152: 627-35. Il primo studio che ha dimostrato la superiorità di prasugrel con aspirina verso clopidogrel con aspirina in termini di riduzione degli eventi ischemici in pazienti con sindromi coronariche acute sottoposti ad intervento coronarico percutaneo. L'articolo riporta i risultati di efficacia e sicurezza.
70. Wiviott SD, Braunwald E, McCabe CH, et al, for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
71. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007; 50: 555-62. Le differenze di velocità, ampiezza e riproducibilità dell'inibizione dell'aggregazione piastrinica fra prasugrel e clopidogrel si spiegano sulla base delle differenze del loro metabolismo.
72. EMEA European Medicines Agency. Efient, Riassunto delle caratteristiche del prodotto. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Efient/emea- combined-h984it.pdf [accessed September 18, 2009].
73. Committee for Medicinal Products for Human Use. CHMP Assessment Report for Efient. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Efient/H-984-en6.pdf [accessed September 18, 2009].
74. Montalescot G, Wiviott SD, Braunwald E, et al, for the TRITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI-38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-31
75. US Food and Drug Administration. Risk evaluation and mitigation strategy. NDA 22-307. Proposed Trade Name: Effient (prasugrel). http://www.accessdata. fda.gov/drugsatfda-docs/label/2009/022307s000REMS.pdf [accessed September 18, 2009].
76. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028-33.
77. Wiviott SD, Braunwald E, Angiolillo DJ, et al, for the TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-36.
78. Wiviott SD, Braunwald E, McCabe CH, et al, for the TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371: 1353-63.
79. 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the Platelet Inhibition and Patient Outcomes (PLATO) trial. Am Heart J 2009; 157: 599-605.
80. Mehta SR, Bassand JP, Chrolavicius S, et al, for the CURRENT-OASIS 7 Steering Committee. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008; 156: 1080-8.
81. Murphy SA, Antman EM, Wiviott SD, et al, for the TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008; 29: 2473-9. Con un'analisi particolare, prasugrel ha dimostrato di ridurre, rispetto a clopidogrel, gli eventi cardiovascolari sia iniziali che successivi in pazienti con sindromi coronariche acute sottoposti ad intervento coronarico percutaneo.